Outcomes in COVID-19 bebtelovimab studies
Outcomes in bebtelovimab studies.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BQ.1.1 [Planas ] . Monoclonal antibody use with variants can be associated with prolonged viral loads, clinical deterioration, and immune escape
[Choudhary ] .
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Lilly (RCT) -151%
2.51 [0.10-61.1]
death
1/252
0/128
Improvement, RR [CI] Treatment Control Dryden-Peterson 86%
0.14 [0.01-2.76]
death
0/377
3/377
Kip 20%
0.80 [0.32-2.02]
death/hosp.
6/157
15/314
Molina (PSM) 57%
0.43 [0.11-1.30]
death
3/3,739
11/5,423
Sridhara (PSM) 86%
0.14 [0.01-2.76]
death
0/1,091
3/1,091
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.13
Early treatment 42%
0.58 [0.29-1.16]
10/5,616
32/7,333
42% improvement All studies 42%
0.58 [0.29-1.16]
10/5,616
32/7,333
42% improvement 5 bebtelovimab COVID-19 studies c19 early.org/bt Jun 2023Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.13
Effect extraction pre-specified (most serious outcome) Favors bebtelovimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Lilly (RCT) -151%
2.51 [0.10-61.1]
1/252
0/128
Improvement, RR [CI] Treatment Control Dryden-Peterson 86%
0.14 [0.01-2.76]
0/377
3/377
Molina (PSM) 57%
0.43 [0.11-1.30]
3/3,739
11/5,423
Sridhara (PSM) 86%
0.14 [0.01-2.76]
0/1,091
3/1,091
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.078
Early treatment 60%
0.40 [0.14-1.11]
4/5,459
17/7,019
60% improvement All studies 60%
0.40 [0.14-1.11]
4/5,459
17/7,019
60% improvement 4 bebtelovimab COVID-19 mortality results c19 early.org/bt Jun 2023Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.078
Favors bebtelovimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Molina 59%
0.41 [0.17-1.03]
6/3,739
21/5,423
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.056
Early treatment 59%
0.41 [0.17-1.03]
6/3,739
21/5,423
59% improvement All studies 59%
0.41 [0.17-1.03]
6/3,739
21/5,423
59% improvement 1 bebtelovimab COVID-19 ICU result c19 early.org/bt Jun 2023Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.056
Favors bebtelovimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Lilly (RCT) -27%
1.27 [0.25-6.46]
hosp.
5/252
2/128
Improvement, RR [CI] Treatment Control Dryden-Peterson 29%
0.71 [0.32-1.59]
hosp.
10/377
14/377
Molina (PSM) 56%
0.44 [0.30-0.64]
hosp.
38/3,739
107/5,423
Sridhara (PSM) 11%
0.89 [0.52-1.53]
hosp.
24/1,091
27/1,091
Tau​2 ​ = 0.09, I​2 ​ = 45.6%, p = 0.061
Early treatment 35%
0.65 [0.42-1.02]
77/5,459
150/7,019
35% improvement All studies 35%
0.65 [0.42-1.02]
77/5,459
150/7,019
35% improvement 4 bebtelovimab COVID-19 hospitalization results c19 early.org/bt Jun 2023Tau​2 ​ = 0.09, I​2 ​ = 45.6%, p = 0.061
Favors bebtelovimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Lilly (RCT) -151%
2.51 [0.10-61.1]
death
1/252
0/128
Improvement, RR [CI] Treatment Control Dryden-Peterson 86%
0.14 [0.01-2.76]
death
0/377
3/377
Kip 20%
0.80 [0.32-2.02]
death/hosp.
6/157
15/314
Molina (PSM) 57%
0.43 [0.11-1.30]
death
3/3,739
11/5,423
Sridhara (PSM) 86%
0.14 [0.01-2.76]
death
0/1,091
3/1,091
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.13
Early treatment 42%
0.58 [0.29-1.16]
10/5,616
32/7,333
42% improvement All studies 42%
0.58 [0.29-1.16]
10/5,616
32/7,333
42% improvement 5 bebtelovimab COVID-19 serious outcomes c19 early.org/bt Jun 2023Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.13
Effect extraction pre-specified (most serious outcome) Favors bebtelovimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Lilly (RCT) 36%
0.64 [0.40-1.03]
viral+
33/252
26/128
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.066
Early treatment 36%
0.64 [0.40-1.03]
33/252
26/128
36% improvement All studies 36%
0.64 [0.40-1.03]
33/252
26/128
36% improvement 1 bebtelovimab COVID-19 viral clearance result c19 early.org/bt Jun 2023Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.066
Favors bebtelovimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Lilly (RCT) -151%
2.51 [0.10-61.1]
death
1/252
0/128
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.58
Early treatment -151%
2.51 [0.10-61.1]
1/252
0/128
151% increased risk All studies -151%
2.51 [0.10-61.1]
1/252
0/128
151% increased risk 1 bebtelovimab COVID-19 Randomized Controlled Trials c19 early.org/bt Jun 2023Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.58
Effect extraction pre-specified (most serious outcome) Favors bebtelovimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Lilly (RCT) -151%
2.51 [0.10-61.1]
1/252
0/128
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.58
Early treatment -151%
2.51 [0.10-61.1]
1/252
0/128
151% increased risk All studies -151%
2.51 [0.10-61.1]
1/252
0/128
151% increased risk 1 bebtelovimab COVID-19 RCT mortality result c19 early.org/bt Jun 2023Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.58
Favors bebtelovimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Dryden-Peterson 86%
0.14 [0.01-2.76]
death
0/377
3/377
Improvement, RR [CI] Treatment Control Kip 20%
0.80 [0.32-2.02]
death/hosp.
6/157
15/314
Molina (PSM) 57%
0.43 [0.11-1.30]
death
3/3,739
11/5,423
Sridhara (PSM) 86%
0.14 [0.01-2.76]
death
0/1,091
3/1,091
Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.091
Early treatment 46%
0.54 [0.27-1.10]
9/5,364
32/7,205
46% improvement All studies 46%
0.54 [0.27-1.10]
9/5,364
32/7,205
46% improvement 4 bebtelovimab COVID-19 peer reviewed studies c19 early.org/bt Jun 2023Tau​2 ​ = 0.00, I​2 ​ = 0.0%, p = 0.091
Effect extraction pre-specified (most serious outcome) Favors bebtelovimab
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Lilly (RCT) -151%
2.51 [0.10-61.1]
death
1/252
0/128
Improvement, RR [CI] Treatment Control Lilly (RCT) -201%
3.01 [0.12-73.2]
death
1/127
0/128
Lilly (RCT) -27%
1.27 [0.25-6.46]
hosp.
5/252
2/128
Lilly (RCT) -51%
1.51 [0.26-8.90]
hosp.
3/127
2/128
Lilly (RCT) -2%
1.02 [0.15-7.16]
hosp.
2/125
2/128
Lilly (RCT) 36%
0.64 [0.40-1.03]
viral+
33/252
26/128
Lilly (RCT) 38%
0.62 [0.35-1.10]
viral+
16/127
26/128
Lilly (RCT) 33%
0.67 [0.38-1.17]
viral+
17/125
26/128
Dryden-Peterson 86%
0.14 [0.01-2.76]
death
0/377
3/377
Dryden-Peterson 43%
0.57 [0.28-1.19]
death/hosp.
10/377
17/377
Dryden-Peterson 29%
0.71 [0.32-1.59]
hosp.
10/377
14/377
Kip 20%
0.80 [0.32-2.02]
death/hosp.
6/157
15/314
Molina (PSM) 57%
0.43 [0.11-1.30]
death
3/3,739
11/5,423
Molina 59%
0.41 [0.17-1.03]
ICU
6/3,739
21/5,423
Molina (PSM) 56%
0.44 [0.30-0.64]
hosp.
38/3,739
107/5,423
Molina (PSM) 46%
0.54 [0.38-0.74]
hosp.
48/3,739
116/5,423
Molina (PSM) -33%
1.33 [1.12-1.57]
progression
260/3,739
275/5,423
Sridhara (PSM) 86%
0.14 [0.01-2.76]
death
0/1,091
3/1,091
Sridhara (PSM) 25%
0.75 [0.43-1.31]
death/hosp.
24/1,091
28/1,091
Sridhara (PSM) 11%
0.89 [0.52-1.53]
hosp.
24/1,091
27/1,091
Bebtelovimab COVID-19 outcomes c19 early.org/bt Jun 2023Favors bebtelovimab
Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.
Submit
